Interventional × Bronchiolitis Obliterans Syndrome × Lymphoid × Clear all CAN3001
Phase 3 Recruiting
700 enrolled
A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy
Phase 1/2 Completed
24 enrolled 67 charts
REACH 5
Phase 2 Completed
46 enrolled 21 charts
Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury
Phase 2 Recruiting
51 enrolled
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Phase 1 Recruiting
36 enrolled
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma
Phase 1 Withdrawn
Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia
Phase 2 Completed
19 enrolled
A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma
Phase 1 Completed
27 enrolled
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
Phase 1/2 Completed
95 enrolled 13 charts
Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
Phase 1/2 Completed
96 enrolled 13 charts
A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.
Phase 1 Completed
24 enrolled
Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
Phase 1/2 Completed
260 enrolled 33 charts
Phase I Study of Milatuzumab for Graft Versus Host Disease
Phase 1 Terminated
12 enrolled
RESONATEâ„¢
Phase 3 Completed
391 enrolled 14 charts
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
Phase 2 Completed
271 enrolled 32 charts
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis
Phase 3 Completed
266 enrolled 58 charts
ProT4
Phase 2 Unknown
114 enrolled
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Phase 3 Completed
666 enrolled 110 charts
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Phase 3 Completed
1,101 enrolled 46 charts
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia
Phase 2 Completed
15 enrolled 10 charts
Ofatumumab in Japanese Patients With CD20 Positive Follicular Lymphoma or Chronic Lymphocytic Leukemia
Phase 1 Completed
6 enrolled
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
Phase 3 Terminated
2,867 enrolled 77 charts
Revlimid® as Consolidation Treatment Chronic Lymphocytic Leukemia
Phase 2 Terminated
11 enrolled 4 charts
A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant Disease
Phase 1 Completed
48 enrolled 27 charts
Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL
Phase 2/3 Withdrawn
Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia
Phase 2 Completed
65 enrolled 8 charts
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis
Phase 3 Completed
95 enrolled 37 charts
A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
Phase 2 Completed
21 enrolled
ZicBol
Phase 4 Completed
26 enrolled
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
Phase 3 Completed
901 enrolled 56 charts
A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
Phase 3 Completed
960 enrolled 55 charts
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia
Phase 2 Completed
86 enrolled 15 charts
A Safety and Tolerability Study of PCI-24781 in Subjects With Cancer
Phase 1 Completed
7 enrolled
Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia
Phase 1/2 Completed
25 enrolled
Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies
Phase 1 Completed
50 enrolled
BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia
Phase 1 Completed
CRC005
Phase 2 Unknown
31 enrolled